G7048
Proguanil hydrochloride
≥95% (HPLC)
Synonym(s):
Chlorguanide, N1-(4-Chlorophenyl)-N5-isopropylbiguanide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C11H16ClN5·HCl
CAS Number:
Molecular Weight:
290.19
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51101906
EC Number:
211-283-7
MDL number:
Quality Level
assay
≥95% (HPLC)
form
solid
storage condition
desiccated
solubility
acetonitrile: water: ~1 mg/mL (60/40)
originator
AstraZeneca
storage temp.
2-8°C
SMILES string
Cl.CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1
InChI
1S/C11H16ClN5.ClH/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9;/h3-7H,1-2H3,(H5,13,14,15,16,17);1H
InChI key
SARMGXPVOFNNNG-UHFFFAOYSA-N
Application
Proguanil (chlorguanide) may be used in anti-parasitic protozoan drug development to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an antimalarial drug.
Biochem/physiol Actions
Chlorguanide (proguanil) is combined with atovaquone for malaria prophylaxis. The two compounds act synergistically to inhibit the plasmodial dihydrofolate reductase (DHFR) and interrupt the electron transport chain. Mutations in DHFR account for the development of resistant strains.
Proguanil hydrochloride is antimalarial. Dihydrofolate reductase inhibitor
Features and Benefits
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Proguanil hydrochloride
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Carine Van Malderen et al.
Malaria journal, 11, 139-139 (2012-05-02)
Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy
Allan Pamba et al.
Blood, 120(20), 4123-4133 (2012-09-21)
Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once daily for 3 days), 95 G6PD-deficient hemizygous
Miriam K Laufer et al.
PloS one, 7(8), e42284-e42284 (2012-08-23)
The predominance of chloroquine-susceptible falciparum malaria in Malawi more than a decade after chloroquine's withdrawal permits contemplation of re-introducing chloroquine for targeted uses. We aimed to compare the ability of different partner drugs to preserve chloroquine efficacy and prevent the